Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lauren Lupino"'
Autor:
Paul Murray, Lauren Lupino, Tracey Perry, Elizabeth J. Soilleux, Robert Hollows, Ciaran B J Woodman, Sandra Margielewska, Daniela Liebelt, Maha Ibrahim, Daniel Krappmann, Sarah Spiegel, Reuben Tooze, Eszter Nagy, Katerina Vrzalikova, Wenbin Wei, Martina Vockerodt, Maizaton Abdullah, Helen Curley, Mathew Care, Jeremy C. Allegood, Gary M. Reynolds
Publikováno v:
Leukemia
Leukemia 32, 214-223 (2017)
Leukemia 32, 214-223 (2017)
The Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma (HL) are characterised by the aberrant activation of multiple signalling pathways. Here we show that a subset of HL displays altered expression of sphingosine-1-phosphate (S1P) receptors
Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC subtype diffuse large B cell lymphoma
Autor:
Tracey Perry, Dieter Kube, Stephen Foster, Matthew A. Care, Reuben Tooze, Martina Vockerodt, Graham S. Taylor, Robert Hollows, Daniel Krappmann, Lauren Lupino, Eszter Nagy, Katerina Vrzalikova, Wenbin Wei, William Simmons, Zbigniew Rudzki, Sandra Margielewska, Maizaton Abdullah, Gary M. Reynolds, Alexandra Schrader, Paul Murray, Alexander C Dowell, Maha Ibrahim, Ciaran B J Woodman
Publikováno v:
J. Pathol. 248, 142-154 (2019)
The Epstein-Barr virus (EBV) is found almost exclusively in the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), yet its contribution to this tumour remains poorly understood. We have focused on the EBV-encoded latent membrane
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b3487bf6e83c5fc5f8d38580573da0
https://eprints.whiterose.ac.uk/142102/1/Vockerodt_et_al-2019-The_Journal_of_Pathology.pdf
https://eprints.whiterose.ac.uk/142102/1/Vockerodt_et_al-2019-The_Journal_of_Pathology.pdf
Publikováno v:
Cancer Research. 80:2657-2657
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma. Currently, approximately 40% of DLBCL patients treated with standard of care therapies, which include a combination of immunotherapy (rituximab; R) and chemotherap